Certara’s regulatory software moat and restructuring upside create asymmetric five-year value, but weak services execution keeps the near-term investment case balanced.
Overview
Certara is a specialized healthcare technology company combining recurring biosimulation software with model-informed drug-development services. Its platforms are used by more than 2,600 customers and are integrated into the review workflows of 20 global regulatory bodies, including the FDA and EMA, creating meaningful switching costs and regulatory lock-in. **The portfolio is becoming more software-centric:** software contributed 53% of continuing revenue in Q2 2026, up from 40% two years earlier, after the May 2026 sale of the lower-margin Regulatory and Medical Writing business. Q2 continuing revenue rose only 1% year over year to $93.27 million and missed consensus by 5.35%; adjusted EBITDA fell 3% to $26.20 million, with margin declining to 28.1%, while GAAP continuing-operations net loss was $6.08 million. Management reaffirmed FY2026 revenue guidance of $367.00 million–$382.00 million, or 0%–4% growth, but reduced adjusted EBITDA margin guidance to 29%–31% and forecast adjusted diluted EPS of $0.31–$0.36. The near-term catalyst is execution of a 5% workforce reduction expected to generate $13.00 million of run-rate savings, alongside conversion of a 27% services pipeline increase. At $7.80, the report’s probability-weighted five-year target is $17.45, but execution and leadership-transition risks justify a balanced view.